

TABLE 207: NEUTROPENIA/THROMBOCYTOPENIA

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	NEUTROPENIA			THROMBOCYTOPENIA		
			n	N	%	n	N	%
Bacon et al., 2011 RESPOND2	1	(1) PR48	8	80	10%	NR		
		(74) B32 PR36-48 RGT	23	162	14%			
Forns et al., 2015 C-SALVAGE	1	(23) GRZ12 + ELB12 + RBV12	1	79	1%	1	79	1%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	0	10	0%	NR		
Gane et al., 2014-2 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%	NR		
Gane et al., 2014-3 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%	NR		
Forns et al., 2014 PROMISE	1	(1) PR48	29	133	22%	NR		
		(42) SIM12 PR24-48 RGT	46	260	18%			
Jensen et al., 2015 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	88	398	22%	16	398	4%
Lawitz et al., 2014	2+3	(40) SOF12 + PR12	11	47	23%	7	47	15%
Lawitz et al., 2014 COSMOS	1	(5) SIM12 + SOF12	0	14	0%	NR		
		(72) SOF12 + SIM12 + RBV12	0	27	0%			
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	0	205	0%	NR		
Pol et al., 2015 NA	1	(40) SOF12 + PR12	18	80	23%	NR		
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	52	384	14%	36	384	9%
		(68) SIM12 PR48	69	379	18%	25	379	7%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	14	132	11%	NR		
		(39) T12 PR48 q8	38	266	14%			
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	11	66	17%	NR		

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	NEUTROPENIA			THROMBOCYTOPENIA		
			n	N	%	n	N	%
		(68) SIM12 PR48	18	66	27%			

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q.d. = once daily; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.